TCL Archive New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years October 26, 2012
TCL Archive Coulter And Venture Capital Firm Form Company To Develop B1 Antibody For NHL April 28, 1995
TCL Archive Institutinal Training Awards Hardest Hit As New Budget Cuts Will Slash Into Noncompeting Grants March 13, 1981